The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?
Open Access
- 15 July 2021
- journal article
- review article
- Published by Touch Medical Media, Ltd. in Heart International
- Vol. 15 (1) , 7-13
Abstract
There are several beneficial effects of statins on the progression of atherosclerosis, and there have been significant advancements in pharmacotherapies forKeywords
Funding Information
- This article is published under the Creative Commons Attribution Non-commercial License.
This publication has 58 references indexed in Scilit:
- Residual macrovascular risk in 2013: what have we learned?Cardiovascular Diabetology, 2014
- Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trialJournal of Clinical Lipidology, 2014
- Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR StudiesAmerican Journal of Cardiovascular Drugs, 2013
- Omega-3 Fatty Acids and Cardiovascular DiseaseJACC, 2011
- OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial InfarctionCirculation, 2010
- n–3 Fatty Acids and Cardiovascular Events after Myocardial InfarctionNew England Journal of Medicine, 2010
- Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)Atherosclerosis, 2008
- Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysisThe Lancet, 2007
- Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trialThe Lancet, 1999
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999